Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2021
Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- High- and low-dose topiramate for the treatment of persons with alcohol use disorder who smoke cigarettes: A randomized control trial.Alcohol, clinical & experimental research · 2025Trial
- Neural cue reactivity and intrinsic functional connectivity in individuals with alcohol use disorder following treatment with topiramate or naltrexone.Psychopharmacology · 2025Trial
- Moderation of treatment outcomes by polygenic risk for alcohol-related traits in placebo-controlled trials of topiramate.Alcohol, clinical & experimental research · 2025Trial
- An intensive longitudinal examination of topiramate treatment for alcohol use disorder: a secondary analysis of data from a randomized controlled trial.Addiction (Abingdon, England) · 2023Trial
- Post-treatment effects of topiramate on alcohol-related outcomes: A combined analysis of two placebo-controlled trials.Addiction biology · 2022Trial
- Topiramate decreases the salience of motivationally relevant visual cues among smokers with alcohol use disorder.Alcoholism, clinical and experimental research · 2022Trial
- Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder.Drug and alcohol dependence · 2021Trial
- Multi-ancestry genome-wide association study of topiramate's effects on heavy alcohol use.Alcohol, clinical & experimental research · 2025Article
- GRIK1 genotype and effect of topiramate for alcohol use: a systematic review.Journal of pharmaceutical health care and sciences · 2025Article
- Next-generation biomarkers for alcohol consumption and alcohol use disorder diagnosis, prognosis, and treatment: A critical review.Alcohol, clinical & experimental research · 2025Review
- A Bayesian zero-inflated beta-binomial model for longitudinal data with group-specific changepoints.Statistics in medicine · 2024Article
- Prevalence and Treatment of Substance Misuse in Older Adults: Beyond Early Adulthood.Substance abuse and rehabilitation · 2024Review
- Association of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data.Addiction (Abingdon, England) · 2022Article
- Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review.Frontiers in pharmacology · 2022Review
- World Health Organization risk drinking levels as a treatment outcome measure in topiramate trials.Alcoholism, clinical and experimental research · 2021Article
- Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives.International journal of molecular sciences · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
In a prior study, topiramate reduced heavy drinking among individuals who sought to reduce their drinking, with the effect moderated by a single nucleotide polymorphism (SNP; rs2832407) in GRIK1, which encodes the kainate GluK1 receptor subunit (Kranzler et al. 2014). The present study sought to replicate prospectively the effect of topiramate and rs2832407 in patients with DSM-5 alcohol use disorder (AUD) who sought to reduce or stop their drinking. We stratified the randomization on genotype (rs2832407*C-allele homozygotes vs. A-allele carriers) and assigned 170 European-American participants (71.2% male) to receive 12 weeks of treatment with topiramate (N = 85), at a maximal daily dosage of 200 mg, or matching placebo (N = 85). At each of nine treatment visits participants received brief counseling to reduce drinking and increase abstinent days. We hypothesized that topiramate-treated patients with the rs2832407*CC genotype would reduce heavy drinking days (HDDs) more than the other three groups. The rate of treatment completion was 91.8% in both groups. The mean number of HDDs per week in the placebo group was 1.67 (95% CI = (1.29, 2.16), p = 0.0001) times greater than in the topiramate group, which was confirmed by the topiramate group's significantly greater reduction in the concentration of the liver enzyme γ-glutamyltransferase and lower alcohol-related problems score. There was no significant difference in topiramate's effect on HDDs between genotype groups. Although consistent with other studies showing a reduction in heavy drinking with topiramate treatment, the prior finding of a moderating effect of rs2832407 genotype was not replicated in this prospective trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.